Genomma Lab Internacional, S.A.B. de C.V. GNMLF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 971.61M | 1.20B | 947.62M | 924.95M | 937.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 971.61M | 1.20B | 947.62M | 924.95M | 937.88M |
| Cost of Revenue | 363.15M | 440.46M | 350.78M | 343.81M | 344.03M |
| Gross Profit | 608.46M | 760.18M | 596.84M | 581.14M | 593.85M |
| SG&A Expenses | 411.87M | 510.66M | 397.56M | 384.55M | 397.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 2.29M | -2.06M | -1.82M | -1.80M | -5.46M |
| Total Operating Expenses | 777.31M | 949.06M | 746.52M | 726.56M | 736.48M |
| Operating Income | 194.30M | 251.58M | 201.10M | 198.39M | 201.40M |
| Income Before Tax | 138.99M | 161.00M | 130.23M | 127.92M | 123.73M |
| Income Tax Expenses | 41.63M | 51.10M | 41.88M | 43.29M | 38.63M |
| Earnings from Continuing Operations | 97.36 | 109.90 | 88.35 | 84.62 | 85.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -26.80M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.36M | 109.90M | 88.35M | 84.62M | 58.29M |
| EBIT | 194.30M | 251.58M | 201.10M | 198.39M | 201.40M |
| EBITDA | 215.05M | 272.24M | 221.28M | 218.15M | 222.02M |
| EPS Basic | 0.09 | 0.14 | 0.14 | 0.13 | 0.11 |
| Normalized Basic EPS | 0.08 | 0.13 | 0.11 | 0.11 | 0.10 |
| EPS Diluted | 0.09 | 0.14 | 0.14 | 0.13 | 0.11 |
| Normalized Diluted EPS | 0.08 | 0.13 | 0.11 | 0.11 | 0.10 |
| Average Basic Shares Outstanding | 4.40B | 3.53B | 3.56B | 3.57B | 3.58B |
| Average Diluted Shares Outstanding | 4.40B | 3.53B | 3.56B | 3.57B | 3.58B |
| Dividend Per Share | 0.03 | 0.04 | 0.04 | 0.04 | 0.07 |
| Payout Ratio | 45.49% | 49.15% | 48.43% | 48.74% | 68.09% |